Status:
COMPLETED
Saliva and Extracellular Vesicles for Parkinson's Disease
Lead Sponsor:
Fondazione Don Carlo Gnocchi Onlus
Collaborating Sponsors:
Azienda Ospedaliero Universitaria di Cagliari
Conditions:
Parkinson's Disease and Parkinsonism
Eligibility:
All Genders
50-85 years
Brief Summary
Rehabilitation is crucial in the treatment of people with Parkinson's disease (PD) as it can ameliorate motor and non-motor impairments, improving their clinical profile and quality of life. Consideri...
Detailed Description
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms such as bradykinesia, tremor, rigidity and postural instability. An accurate rehabilitation program designed co...
Eligibility Criteria
Inclusion
- For Pakinson's disease: diagnosis following "MDS clinical diagnostic criteria for Parkinson's disease" (Postuma et al. Movement Disorders vol. 30 1591-1601, 2015), with Hoehn\&Yahr between 1 and 3.
- The diagnosis of Progressive Supranuclear Palsy will be made according to the criteria of the Movement Disorders Society (Höglinger et al. Mov. Disord. 32, 853-864, 2017). The diagnosis of Corticobasal Syndrome will be made according to the 2013 Armstrong criteria (Armstrong et al. Neurology 80, 496-503, 2013).
- The diagnosis of multiple system atrophy will be made according to the Gilman criteria of The diagnosis of Behavior Disorder in REM phase will be made according to the criteria of the "International Classification of Sleep Disorders, Third Edition (ICSD-3)".
Exclusion
- For all the experimental groups considered and for healthy controls, subjects with concomitant chronic and / or inflammatory diseases of the oral cavity, other systemic diseases (eg anemia, cardiovascular or respiratory diseases), oncological or infectious diseases will be excluded.
- Vascular parkinsonisms, monogenic parkinsonisms will also be excluded as well as iatrogenic parkinsonisms, parkinsonisms secondary to exposure to known neurotoxins; parkinsonisms secondary to tumor lesions; parkinsonisms due to normotensive hydrocephalus; subjects with a form of dementia, severe speech disorders and other psychiatric and / or neurological pathologies.
Key Trial Info
Start Date :
December 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
165 Patients enrolled
Trial Details
Trial ID
NCT05320250
Start Date
December 15 2021
End Date
December 31 2024
Last Update
January 13 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliero - Universitaria di Cagliari
Cagliari, Italy
2
IRCCS Fondazione Don Carlo Gnocchi
Florence, Italy, 50100
3
IRCCS S. Maria Nascente, Fondazione Don Carlo Gnocchi ONLUS
Milan, Italy, 20148
4
Fondazione Don Gnocchi, Centro "S. Maria ai Servi"
Parma, Italy